JP7871988B2 - Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 - Google Patents
Nrp1結合ドメインを含む二重特異性抗体およびその使用方法Info
- Publication number
- JP7871988B2 JP7871988B2 JP2024557935A JP2024557935A JP7871988B2 JP 7871988 B2 JP7871988 B2 JP 7871988B2 JP 2024557935 A JP2024557935 A JP 2024557935A JP 2024557935 A JP2024557935 A JP 2024557935A JP 7871988 B2 JP7871988 B2 JP 7871988B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- binding
- sequence shown
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325312P | 2022-03-30 | 2022-03-30 | |
| US202263325317P | 2022-03-30 | 2022-03-30 | |
| US63/325,312 | 2022-03-30 | ||
| US63/325,317 | 2022-03-30 | ||
| PCT/US2023/016963 WO2023192514A1 (en) | 2022-03-30 | 2023-03-30 | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026080898A Division JP2026133506A (ja) | 2022-03-30 | 2026-05-13 | Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511135A JP2025511135A (ja) | 2025-04-15 |
| JP2025511135A5 JP2025511135A5 (cg-RX-API-DMAC7.html) | 2025-11-04 |
| JP7871988B2 true JP7871988B2 (ja) | 2026-06-09 |
Family
ID=86184900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024557935A Active JP7871988B2 (ja) | 2022-03-30 | 2023-03-30 | Nrp1結合ドメインを含む二重特異性抗体およびその使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12692315B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4499696A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7871988B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240163751A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119403831A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023245728A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3255754A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024002899A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024014799A2 (cg-RX-API-DMAC7.html) |
| CR (1) | CR20240462A (cg-RX-API-DMAC7.html) |
| IL (1) | IL315960A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024011978A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023192514A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL315960A (en) | 2022-03-30 | 2024-11-01 | Pinetree Therapeutics Inc | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| AU2023317484A1 (en) * | 2022-07-30 | 2025-03-13 | Pinetree Therapeutics, Inc. | Compositions for targeted lysosomal degradaton and methods of use thereof |
| IL320410A (en) * | 2022-11-07 | 2025-06-01 | Pinetree Therapeutics Inc | Combination therapy involving bispecific antibodies containing an NRP1 binding domain |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514972A (ja) | 2005-11-08 | 2009-04-09 | ジェネンテック・インコーポレーテッド | ニューロピリンアンタゴニスト |
| US20190062375A1 (en) | 2016-03-29 | 2019-02-28 | Ajou University Industry-Academic Cooperation Foun Dation | Composition for overcoming resistance to egfr-targeting agent |
| WO2020027224A1 (ja) | 2018-07-31 | 2020-02-06 | 国立大学法人東京大学 | 新たな結合特異性を抗体に付与する超汎用法 |
| WO2020079280A1 (en) | 2018-10-19 | 2020-04-23 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers |
| JP2020517659A (ja) | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | Egfr陽性癌の治療のためのt細胞リダイレクト二重特異性抗体 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5545130A (en) | 1992-04-08 | 1996-08-13 | Genetronics, Inc. | Flow through electroporation method |
| US5702359A (en) | 1995-06-06 | 1997-12-30 | Genetronics, Inc. | Needle electrodes for mediated delivery of drugs and genes |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5869326A (en) | 1996-09-09 | 1999-02-09 | Genetronics, Inc. | Electroporation employing user-configured pulsing scheme |
| US20020173629A1 (en) | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6055453A (en) | 1997-08-01 | 2000-04-25 | Genetronics, Inc. | Apparatus for addressing needle array electrodes for electroporation therapy |
| US6216034B1 (en) | 1997-08-01 | 2001-04-10 | Genetronics, Inc. | Method of programming an array of needle electrodes for electroporation therapy of tissue |
| US6241701B1 (en) | 1997-08-01 | 2001-06-05 | Genetronics, Inc. | Apparatus for electroporation mediated delivery of drugs and genes |
| US6208893B1 (en) | 1998-01-27 | 2001-03-27 | Genetronics, Inc. | Electroporation apparatus with connective electrode template |
| US6120493A (en) | 1998-01-27 | 2000-09-19 | Genetronics, Inc. | Method for the introduction of therapeutic agents utilizing an electroporation apparatus |
| US6302874B1 (en) | 1998-07-13 | 2001-10-16 | Genetronics, Inc. | Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications |
| US6192270B1 (en) | 1998-08-14 | 2001-02-20 | Genetronics, Inc. | Apparatus and method for the delivery of drugs and genes into tissue |
| US6150148A (en) | 1998-10-21 | 2000-11-21 | Genetronics, Inc. | Electroporation apparatus for control of temperature during the process |
| US7245963B2 (en) | 2002-03-07 | 2007-07-17 | Advisys, Inc. | Electrode assembly for constant-current electroporation and use |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗her2抗体改変体 |
| ME01803B (me) | 2004-08-05 | 2010-12-31 | Genentech Inc | Humanizovani anti-cmet antagonisti |
| GB0503546D0 (en) | 2005-02-21 | 2005-03-30 | Hellenic Pasteur Inst | Antibody |
| CA2628253A1 (en) | 2005-11-03 | 2007-08-30 | Genentech, Inc. | Therapeutic anti-her2 antibody fusion polypeptides |
| US20100143340A1 (en) | 2006-12-13 | 2010-06-10 | Schering Corporation | Methods and compositions for treating cancer |
| PL2155788T3 (pl) * | 2007-04-03 | 2013-02-28 | Amgen Res Munich Gmbh | Swoiste międzygatunkowe bispecyficzne czynniki wiążące |
| US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
| US20140112911A9 (en) | 2008-12-02 | 2014-04-24 | Liliane Goetsch | Novel anti-cmet antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| WO2010099186A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Her2 antibody compositions |
| EP2287197A1 (en) | 2009-08-21 | 2011-02-23 | Pierre Fabre Medicament | Anti-cMET antibody and its use for the detection and the diagnosis of cancer |
| WO2011057064A1 (en) | 2009-11-05 | 2011-05-12 | Brian Long | Igf1r inhibitor based treatment of prostate cancer |
| CN102167742B (zh) | 2010-02-25 | 2014-05-14 | 上海百迈博制药有限公司 | 一种全人源抗her2单克隆抗体、其制备方法及用途 |
| EP3904391B1 (en) | 2010-03-10 | 2024-07-10 | Genmab A/S | Monoclonal antibodies against c-met |
| WO2011143408A1 (en) | 2010-05-13 | 2011-11-17 | Genentech, Inc. | Use of neuropilin-1 antagonists for the treatment of cancer |
| JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
| AU2012255920A1 (en) | 2011-05-18 | 2013-11-07 | Merck Sharp & Dohme Corp. | Therapeutic anti-IGF1R combinations |
| CN102492039B (zh) | 2011-11-21 | 2015-03-11 | 无锡天演生物技术有限公司 | 全人源抗人her2单抗 |
| EP2863947B1 (en) | 2012-06-21 | 2018-03-07 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind igf1r |
| WO2014189303A1 (ko) | 2013-05-23 | 2014-11-27 | 아주대학교산학협력단 | 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질 |
| JP6541237B2 (ja) | 2014-03-06 | 2019-07-10 | ナショナル リサーチ カウンシル オブ カナダ | インスリン様成長因子1受容体特異的抗体及びそれらの使用 |
| EP3114142B1 (en) | 2014-03-06 | 2019-06-05 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| US9975960B2 (en) | 2014-05-09 | 2018-05-22 | Samsung Electronics Co., Ltd. | Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same |
| KR101551306B1 (ko) | 2015-03-23 | 2015-09-09 | 아주대학교산학협력단 | 뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도 |
| ES3043088T3 (en) | 2015-06-17 | 2025-11-24 | Hoffmann La Roche | Anti-her2 antibodies and methods of use |
| WO2017171373A2 (ko) * | 2016-03-29 | 2017-10-05 | 아주대학교산학협력단 | Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물 |
| KR101985299B1 (ko) | 2016-06-03 | 2019-09-03 | 삼성전자주식회사 | 항-c-Met/항-Nrp1 이중 특이 항체 |
| US10167342B2 (en) | 2016-08-29 | 2019-01-01 | Fazel Shokri | Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment |
| LT3512882T (lt) | 2016-09-14 | 2021-06-25 | Merck Patent Gmbh | Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui |
| JOP20190134A1 (ar) | 2016-12-23 | 2019-06-02 | Potenza Therapeutics Inc | بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها |
| EP3680250A4 (en) | 2017-09-08 | 2021-07-14 | Ajou University Industry-Academic Cooperation Foundation | COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1) |
| KR102054389B1 (ko) | 2017-10-26 | 2019-12-11 | 아주대학교산학협력단 | 뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도 |
| JP2022510218A (ja) | 2018-11-30 | 2022-01-26 | メモリアル スローン ケタリング キャンサー センター | ヘテロ二量体四価特異性抗体およびこれらの使用 |
| MX2021008121A (es) | 2019-01-03 | 2021-12-10 | Inst Nat Sante Rech Med | Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer. |
| WO2022026943A2 (en) | 2020-07-31 | 2022-02-03 | Pinetree Therapeutics, Inc. | Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections |
| IL315960A (en) | 2022-03-30 | 2024-11-01 | Pinetree Therapeutics Inc | Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof |
| IL320410A (en) | 2022-11-07 | 2025-06-01 | Pinetree Therapeutics Inc | Combination therapy involving bispecific antibodies containing an NRP1 binding domain |
| EP4754135A1 (en) | 2023-07-28 | 2026-06-10 | Pinetree Therapeutics, Inc. | Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof |
-
2023
- 2023-03-30 IL IL315960A patent/IL315960A/en unknown
- 2023-03-30 CN CN202380044206.1A patent/CN119403831A/zh active Pending
- 2023-03-30 US US18/128,928 patent/US12692315B2/en active Active
- 2023-03-30 CR CR20240462A patent/CR20240462A/es unknown
- 2023-03-30 CA CA3255754A patent/CA3255754A1/en active Pending
- 2023-03-30 EP EP23719560.7A patent/EP4499696A1/en active Pending
- 2023-03-30 KR KR1020247036173A patent/KR20240163751A/ko active Pending
- 2023-03-30 JP JP2024557935A patent/JP7871988B2/ja active Active
- 2023-03-30 AU AU2023245728A patent/AU2023245728A1/en active Pending
- 2023-03-30 WO PCT/US2023/016963 patent/WO2023192514A1/en not_active Ceased
-
2024
- 2024-09-27 CL CL2024002899A patent/CL2024002899A1/es unknown
- 2024-09-27 MX MX2024011978A patent/MX2024011978A/es unknown
- 2024-10-29 CO CONC2024/0014799A patent/CO2024014799A2/es unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514972A (ja) | 2005-11-08 | 2009-04-09 | ジェネンテック・インコーポレーテッド | ニューロピリンアンタゴニスト |
| US20190062375A1 (en) | 2016-03-29 | 2019-02-28 | Ajou University Industry-Academic Cooperation Foun Dation | Composition for overcoming resistance to egfr-targeting agent |
| JP2020517659A (ja) | 2017-04-24 | 2020-06-18 | イクノス サイエンシズ エスエー | Egfr陽性癌の治療のためのt細胞リダイレクト二重特異性抗体 |
| WO2020027224A1 (ja) | 2018-07-31 | 2020-02-06 | 国立大学法人東京大学 | 新たな結合特異性を抗体に付与する超汎用法 |
| WO2020079280A1 (en) | 2018-10-19 | 2020-04-23 | Ichnos Sciences SA | T cell redirecting bispecific antibodies for the treatment of squamous cell cancers |
Non-Patent Citations (1)
| Title |
|---|
| Cancer Letters,2019年,vol.466,p.23-34 |
Also Published As
| Publication number | Publication date |
|---|---|
| CR20240462A (es) | 2024-12-11 |
| AU2023245728A1 (en) | 2024-09-26 |
| JP2025511135A (ja) | 2025-04-15 |
| CA3255754A1 (en) | 2023-10-05 |
| KR20240163751A (ko) | 2024-11-19 |
| US12692315B2 (en) | 2026-07-28 |
| CL2024002899A1 (es) | 2025-02-07 |
| EP4499696A1 (en) | 2025-02-05 |
| CO2024014799A2 (es) | 2024-11-18 |
| CN119403831A (zh) | 2025-02-07 |
| IL315960A (en) | 2024-11-01 |
| MX2024011978A (es) | 2025-02-10 |
| WO2023192514A1 (en) | 2023-10-05 |
| US20240101682A1 (en) | 2024-03-28 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251023 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251023 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20251023 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251118 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260216 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260414 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260507 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7871988 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |